[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"bariatric-surgery-patients\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:bariatric-surgery-patients":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,11,0,[8,48,77,101,125,147,166,190,223,252,273],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":33,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100589244","identification-of-pre-surgical-phenotypic-indicators-predictive-of-quality-of-life-trajectories-in-obese-patients-following-bariatric-surgery-100589244",false,"NCT06951893","Identification of Pre-surgical Phenotypic Indicators Predictive of Quality of Life Trajectories in Obese Patients Following Bariatric Surgery","PHENOBEQOL73","Inclusion Criteria:\n\n* patient \\> 18years old\n* Integrated into the GEROM73 surgical program and starting the intra-hospital program\n\nExclusion Criteria:\n\n* Patients in a state of psychiatric decompensation\n* Patients with cognitive disorders\n* Patients with difficulties understanding the French language, spoken or written\n* Pregnant, parturient, or breastfeeding women","ALL","18 Years",{"count":19,"type":20},165,"ESTIMATED","INTERVENTIONAL",[23],"NA","This study aims to identify pre-operative phenotypic determinants predictive of quality of life trajectories in post-bariatric surgery patients. In addition, this study will have as a secondary objective the highlighting of a potential link between post-surgery quality of life trajectories and those of anxiety\u002Fdepression scores, eating behaviors and body mass indices.\n\nThis study will be conducted during the usual care of patients undergoing the GEROM73 program, lasting a total of 30 months.\n\nThe GEROM73 program includes care for the six months preceding bariatric surgery and the 24 months following surgery. This program supports patients throughout their bariatric care..\n\nThroughout the GEROM73 program, patients will complete questionnaires on anxiety, depression, eating disorders, Impact of Weight on Quality Of Life.\n\nPatients' weight, body mass index and body schema will also be measured throughout the GEROM program.",[26,27,28,29,30,31,32],"Obesity, Morbid","Obesity and Overweight","Bariatric Surgery","Bariatric Surgery Patients","Bariatric Surgery Patient","Bariatric Surgery (Sleeve Gastrectomy )","Bypass, Gastric",[34,14],"GEROM73","RECRUITING","2026-06-09",{"date":38,"type":39},"2026-06-10","ACTUAL",{"date":41,"type":39},"2025-06-17",{"date":43,"type":20},"2030-09-09",{"name":45,"class":46},"Centre Hospitalier Metropole Savoie","OTHER",1,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":4,"eligibilityCriteria":54,"healthyVolunteers":55,"sex":16,"minAge":17,"maxAge":56,"enrollmentInfo":57,"targetDuration":4,"studyType":59,"phases":4,"briefSummary":60,"conditions":61,"keywords":62,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":47},"100606680","the-metabolic-and-genetic-drivers-of-body-composition-changes-following-weight-loss-surgery-100606680","NCT07178704","The Metabolic and Genetic Drivers of Body Composition Changes Following Weight Loss Surgery","PILOT STUDY: The Metabolic and Genetic Drivers of Body Composition Changes Following Weight Loss Surgery","Inclusion Criteria (Healthy Volunteers):\n\n* Age: 30 to 50 years at time of consent\n* BMI: 20-25 kg.m-2\n* Male or Female\n* All races and ethnic backgrounds\n* Ability to speak and read English\n* Subject has provided informed consent in a manner approved by the IRB and is willing and able to comply with the trial procedures.\n\nInclusion Criteria (Bariatric Surgery Patients):\n\n* Age: 18 to 65 years at time of consent\n* BMI: 35-50 kg.m-2\n* Scheduled to undergo bariatric surgery at UTMB\n* All races and ethnic backgrounds\n* Ability to speak and read English\n* Subject has provided informed consent in a manner approved by the IRB and is willing and able to comply with the trial procedures.\n\nAdditional inclusion criteria for patients undergoing enhanced metabolic assessment:\n\n* Age: restricted to 30 to 50 years of age\n* Undergoing gastric bypass surgery\n\nExclusion Criteria (Healthy Volunteers):\n\n* Heart, vascular, or pulmonary disease\n* Uncontrolled blood pressure (systolic BP \\> 170, diastolic BP \\> 95 mmHg)\n* Impaired renal function (creatinine \\> 1.5 mg\u002Fdl)\n* Anemia (hematocrit \\\u003C 33 % or donated blood in the past 12 weeks.)\n* Diabetes mellitus or other untreated endocrine or metabolic disorder\n* Recent (5 years or less) history of cancer\n* Systemic steroids, anabolic steroids, growth hormone, or immunosuppressant use within 6 months.\n* Recent (6 months) adherence to a weight-loss or weight-gain diet, resulting in a weight change of 10% or more.\n* Body mass index \\> 25.5 kg.m-2\n* Body mass index \\\u003C 19.5 kg.m-2 or recent history (\\\u003C 12 months) of disordered eating.\n* Acute infectious disease or chronic infection.\n* Pregnancy or breast-feeding.\n* Recent (1 month) consumption of protein-based sports supplements.\n* Any medical condition that, in the opinion of the investigator, would place the subject at increased risk for participation.\n* Known allergic reaction to any agent under investigation or required by the protocol, including Phenylketonuria.\n* Unable to lie still in a supine position for 10 minutes.\n* History of prior non-compliance or the presence or history of a psychiatric condition (including drug or alcohol addiction) that would, in the opinion of the investigator, make it difficult for the subject to comply with the study procedures or follow the investigators instructions.\n* Concurrent participation in another research study.\n* Use of an investigational agent in the 30 days prior to signing informed consent.\n\nExclusion Criteria (Bariatric Surgery Patients):\n\n* Fails the medical criteria for bariatric surgery.\n* Anemia (hematocrit \\\u003C 33 % or donated blood in the past 12 weeks.)\n* Recent (5 years or less) history of cancer\n* Systemic steroids, anabolic steroids, growth hormone, or immunosuppressant use within 6 months.\n* Body mass index \\\u003C 35 or \\> 50 kg.m-2.\n* Acute infectious disease or chronic infection.\n* Pregnancy or breast-feeding.\n* Any medical condition that, in the opinion of the investigator, would place the subject at increased risk for participation.\n* History of prior non-compliance that would, in the opinion of the investigator, make it difficult for the subject to comply with the study procedures or follow the investigator's instructions.\n* Concurrent participation in another research study.\n* Use of an investigational agent in the 30 days prior to signing informed consent.\n\nAdditional exclusion criteria for patients undergoing enhanced metabolic assessment:\n\n* Known allergic reaction to any agent under investigation or required by the protocol, including Phenylketonuria.\n* Unable to lie still in a supine position for 10 minutes.\n* Previous bariatric surgery or undergoing a procedure other than gastric bypass (e.g. sleeve gastrectomy).",true,"65 Years",{"count":58,"type":20},110,"OBSERVATIONAL","Weight loss surgery is very good at reducing body weight but it can also cause the loss of both muscle and strength. Some patients undergoing weight loss surgery do not achieve their weight loss goals and regain the weight they lost. When this occurs, the loss of muscle and strength combined with the regain of weight can impact the individual's quality of life and ability to remain active and mobile.\n\nThe purpose of this study is to understand the behavioral, biological, and genetic factors that influence the success of weight loss surgery and its impact on muscle mass.\n\nBariatric surgery patients participating in the trial will be monitored prior to, and for a year following weight loss surgery, with data collected about their eating habits, hand grip strength, and the loss of fat, muscle, and body weight following surgery. Some patients will be additionally invited to undergo detailed metabolic assessment, where we will measure how their body uses nutrients it consumes, the composition of their body (e.g. how much lean and fat tissue they have and where it is stored), identify the bacteria living in their gut, and determine their physical performance. In all patients a small sample of gut tissue will be collected at a routine endoscopy performed in advance of weight loss surgery to identify the expression (activity) of genes in their DNA.\n\nHealthy subjects will also be recruited to allow us to compare between healthy weight individuals and those undergoing weight loss surgery. On a single occasion, the healthy volunteers will undergo the same detailed metabolic assessment performed in patients as described above. We will not examine the bacteria living in the gut of the healthy volunteers, nor will we collect gut tissue from these individuals.",[29],[63,64,65,66,67],"Body composition","Sarcopenia","Weight loss surgery","Muscle function","Protein metabolism","2026-05-20",{"date":70,"type":39},"2026-05-22",{"date":72,"type":39},"2025-11-04",{"date":74,"type":20},"2027-08",{"name":76,"class":46},"The University of Texas Medical Branch, Galveston",{"id":78,"slug":79,"hasResults":11,"nctId":80,"briefTitle":81,"officialTitle":82,"acronym":4,"eligibilityCriteria":83,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":84,"targetDuration":4,"studyType":21,"phases":86,"briefSummary":88,"conditions":89,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":47},"100610161","phase-1-semaglutide-sema-for-alcohol-use-disorder-aud-after-metabolic-and-bariatric-surgery-mbs-100610161","NCT07223983","Semaglutide (SEMA) for Alcohol Use Disorder (AUD) After Metabolic and Bariatric Surgery (MBS)","Semaglutide Treatment for Alcohol Use Disorder After Metabolic and Bariatric Surgery: A Pilot Randomized Controlled Trial","Inclusion Criteria:\n\n* Provision of signed and dated informed consent form\n* Stated willingness to comply with all study procedures and availability for the duration of the study (up to 6 months: 3-month treatment plus 3-month follow up)\n* Age 18 and older\n* Have a BMI ≥30 (or BMI ≥27 with a medical comorbidity) and BMI ≤50 kg\u002Fm2\n* Have had laparoscopic Roux-en-Y gastric bypass or sleeve gastrectomy within the past seven years\n* Meet current DSM-5 criteria for Alcohol Use Disorder\n* Be an otherwise healthy subject without uncontrolled medical problems, as determined by the study physician and medical co-investigators\n* Read, comprehend, and write English at a sufficient level to complete study-related materials\n* For females of reproductive potential: use of highly effective contraception and agreement to use such a method during study participation\n\nExclusion Criteria:\n\n* Any of the following: myocardial infarction, stroke, hospitalization for unstable angina, or transient ischemic attack within the past 60 days prior to screening\n* History or presence of chronic or recurrent pancreatitis\n* History of malignant neoplasms within the past 5 years prior to screening\n* Personal or family history of medullary thyroid carcinoma or in patients with Multiple Endocrine Neoplasia syndrome type 2\n* Is currently using other medications for weight loss or other GLP-1 receptor agonists\n* Has a history of allergy or sensitivity to Semaglutide\n* Has a co-existing psychiatric condition that requires hospitalization or more intensive treatment (such as bipolar mood disorders, psychotic illnesses, or severe depression)\n* Has untreated hypertension with a seated systolic blood pressure \\> 160 mmHg, diastolic blood pressure \\> 100 mmHg, or heart rate \\> 100 beats\u002Fminute\n* Has current uncontrolled hypertension\n* Has current uncontrolled Type I or Type II diabetes mellitus\n* Has untreated hypothyroidism with a TSH \\> 1.5 times the upper limit of normal for the test laboratory with repeat value that also exceeds this limit\n* Has active gallbladder disease\n* Has a history of severe renal, hepatic, neurological, chronic pulmonary disease, or any other unstable medical disorder\n* Has a recent history of substance use disorder (with the exception of cannabis or tobacco use disorder) within the past 12 months\n* Is currently engaging in other treatment for Alcohol Use Disorder or making intentional efforts to quit alcohol use\n* Is currently participating in another clinical study in which the subject is or will be exposed to an investigational or a non-investigational drug or device\n* Is breast-feeding, pregnant, or not using a reliable form of birth control\n* Reports active suicidal or homicidal ideation\n* Any disorder, unwillingness or inability, not covered by any of the other exclusion criteria which, in the investigator's opinion, might have jeopardized the participant's safety or compliance with the protocol",{"count":85,"type":20},10,[87],"PHASE1","The purpose of this research study is to evaluate the feasibility of treating Alcohol Use Disorder with Semaglutide after metabolic and bariatric surgery in adults with overweight or obesity.",[90,91,29],"Alcohol Use Disorder","Weight Loss","2026-05-07",{"date":94,"type":39},"2026-05-12",{"date":96,"type":39},"2026-03-06",{"date":98,"type":20},"2026-10-31",{"name":100,"class":46},"Yale University",{"id":102,"slug":103,"hasResults":11,"nctId":104,"briefTitle":105,"officialTitle":106,"acronym":4,"eligibilityCriteria":107,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":56,"enrollmentInfo":108,"targetDuration":4,"studyType":21,"phases":110,"briefSummary":112,"conditions":113,"keywords":4,"overallStatus":116,"whyStopped":4,"lastUpdateSubmitDate":117,"lastUpdatePostDateStruct":118,"startDateStruct":120,"completionDateStruct":122,"leadSponsor":124,"locationsCount":47},"100623574","phase-1-a-multiple-health-behavior-change-mhbc-intervention-for-weight-loss-and-smoking-cessation-for-pre-bariatric-surgery-patients-100623574","NCT07398404","A Multiple Health Behavior Change (MHBC) Intervention for Weight Loss and Smoking Cessation for Pre-Bariatric Surgery Patients","A Multiple Health Behavior Change Intervention for Weight Loss and Smoking Cessation for Pre-Bariatric Surgery Patients","Inclusion Criteria:\n\n* Be 18-65 years old.\n* Be actively considering bariatric surgery.\n* Smoke at least 5 cigarettes daily for the past 3 months.\n* Have a BMI ≥ 30.0 kg\u002Fm2.\n* Not currently taking medications that interact with Naltrexone or Bupropion (e.g., opiates, benzodiazepines).\n* No history of medical conditions that are contraindicated with Naltrexone or - Bupropion (e.g., seizure disorders, uncontrolled hypertension, cardiac issues including history of heart attacks, heart disease, or stroke, history of anorexia or bulimia nervosa).\n* Physically well enough to participate in the intervention (e.g., able to walk independently).\n* Speak\u002Fread\u002Fwrite in English.\n* Not currently pregnant or breastfeeding or have plans to become pregnant or breastfeed during the study.\n* No active suicidal or homicidal ideation.\n\nExclusion Criteria:\n\n* Has an acute medical or psychiatric disorder that would make participation difficult or unsafe.\n* Has suicidal or homicidal ideation that requires immediate attention.\n* Has a predisposition to seizures (e.g., subject with a history or evidence of seizure disorder, febrile seizures during childhood, brain tumor, cerebrovascular disease, or significant head trauma; has a family history of idiopathic seizure disorder or is currently being treated with medications or treatment regimens that lower seizure threshold).\n* Has evidence of a second or third degree heart block, atrial fibrillation, atrial flutter, prolongation of the QTc, or any other finding on the screening electrocardiogram that would preclude safe participation.\n* Has stage 2 hypertension (blood pressure greater than 160\u002F100 or heart rate over 100 beats\u002Fminute).\n* Has elevated bilirubin test or any other liver function test value \\> 5 times the upper limit of normal laboratory criteria.\n* Has a platelet count \\\u003C 100x10 3\u002FuL.\n* Has a history of anorexia nervosa or history of bulimia nervosa.\n* Is currently taking a medication that is contraindicated to Naltrexone or Bupropion (e.g., MAOIs, opiates).\n* Has a history of allergy or sensitivity to Naltrexone or Bupropion.\n* Has a co-existing psychiatric condition that requires hospitalization or more intensive treatment (such as bipolar mood disorders, psychotic illnesses, or severe depression).\n* Has a history of congenital heart disease, cardiovascular disease, cardiac arrhythmias requiring medication, or a history of cerebrovascular pathology including stroke.\n* Has current uncontrolled Type I or Type 2 diabetes mellitus.\n* Has a history of severe renal, hepatic, neurological, chronic pulmonary, or gallbladder disease, or any other unstable medical disorder, including cancer.\n* Has angle closure glaucoma.\n* Has taken an investigational drug in another study within 30 days of study consent.\n* Has been prescribed and taken Naltrexone or Bupropion within 30 days of study consent.\n* Is concurrently enrolled in formal behavioral or pharmacological Substance Use Disorder treatment.\n* Is receiving ongoing treatment with tricyclic antidepressants, xanthines, systemic corticosteroids, nelfinavir, efavirenz, chlorpromazine, MAOIs, central nervous stimulants, or any medication that could interact adversely with the study medications.\n* Has a current pattern of alcohol, benzodiazepine, or other sedative hypnotic use which would preclude safe participation in the study.\n* Requires treatment with opioid-containing medications during the study period.\n* Has a surgery planned other than bariatric surgery.\n* Is currently in jail, prison, or any inpatient overnight facility as required by a court of law or have pending legal action or other legal situation that could prevent participation.\n* Is currently pregnant, breastfeeding, or plans to become pregnant during the study, or is not using a reliable form of birth control.",{"count":109,"type":20},64,[87,111],"PHASE2","The purpose of this research study is to evaluate a multiple health behavior change intervention for weight loss and smoking cessation using medication (Naltrexone + Bupropion) and behavior therapy in adults seeking bariatric surgery. The intervention will be compared to a standard of care control group.",[114,115,29],"Obesity","Smoking Cessation","NOT_YET_RECRUITING","2026-03-17",{"date":119,"type":39},"2026-03-20",{"date":121,"type":20},"2026-07-01",{"date":123,"type":20},"2031-06-30",{"name":100,"class":46},{"id":126,"slug":127,"hasResults":11,"nctId":128,"briefTitle":129,"officialTitle":129,"acronym":130,"eligibilityCriteria":131,"healthyVolunteers":11,"sex":16,"minAge":132,"maxAge":4,"enrollmentInfo":133,"targetDuration":4,"studyType":21,"phases":135,"briefSummary":136,"conditions":137,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":117,"lastUpdatePostDateStruct":139,"startDateStruct":141,"completionDateStruct":143,"leadSponsor":145,"locationsCount":47},"100586349","implementing-an-interdisciplinary-eating-disorder-screening-and-treatment-program-for-post-bariatric-surgery-patients-in-nova-scotia-100586349","NCT06914219","Implementing an Interdisciplinary Eating Disorder Screening and Treatment Program for Post-Bariatric Surgery Patients in Nova Scotia","TEAM-ED","Inclusion Criteria:\n\n* ≥19 years old\n* Between 3- and 18-months post-weight loss surgery.\n* Able to complete English computer-based self-report questionnaires (with adequate accommodation, if necessary).","19 Years",{"count":134,"type":20},250,[23],"The goal of this interventional study is to evaluate the Treatment and Evaluation for After Metabolic Surgery with Eating Disorders (TEAM-ED) program, which combines streamlined access to screening, diagnostic assessment, and treatment with an interdisciplinary team approach to treatment planning, for managing disordered eating in adults who have recently had weight loss surgery in Nova Scotia. The main question it aims to answer is 'can an interdisciplinary program for identifying and managing disordered eating after weight loss surgery be implemented in Nova Scotia?\n\nThis study will determine the feasibility and impact of the TEAM-ED program by assessing the following objectives:\n\n1. Reach (how effectively the program engages the target population \\[post-weight loss surgery patients\\])\n2. Effectiveness (the extent of the program's impact on key clinical outcomes related to disordered eating and weight management)\n3. Adoption (the extent to which the program is adopted and accepted by clinicians)\n4. Implementation (how consistent program delivery is and factors impacting consistent delivery)\n\nParticipants will complete a disordered eating screening questionnaire online every 3 months after weight loss surgery until they reach 18-months post-surgery. Participants found to have disordered eating will be referred to the Nova Scotia Provincial Eating Disorder Service (NSEDPS) for standard disordered eating treatment (brief cognitive behavioral therapy \\[CBT-T\\]) plus treatment plan oversight by both weight loss surgery and eating disorder specialists. Standard outcome measures will be collected at baseline, during eating disorder treatment, post-treatment, and at follow-ups. Participants may also be asked to do a one-on-one research interview about their experiences with the program.",[29,138],"Disordered Eating Behaviors",{"date":140,"type":39},"2026-03-19",{"date":142,"type":39},"2026-03-04",{"date":144,"type":20},"2027-05",{"name":146,"class":46},"Aaron Keshen",{"id":148,"slug":149,"hasResults":11,"nctId":150,"briefTitle":151,"officialTitle":152,"acronym":4,"eligibilityCriteria":153,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":56,"enrollmentInfo":154,"targetDuration":4,"studyType":21,"phases":156,"briefSummary":157,"conditions":158,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":159,"lastUpdatePostDateStruct":160,"startDateStruct":161,"completionDateStruct":163,"leadSponsor":165,"locationsCount":47},"100610169","phase-1-development-of-a-mhbc-intervention-for-weight-loss-and-smoking-cessation-for-pre-bariatric-surgery-patients-100610169","NCT07224087","Development of a MHBC Intervention for Weight Loss and Smoking Cessation for Pre-Bariatric Surgery Patients","Development of a Multiple Health Behavior Change Intervention for Weight Loss and Smoking Cessation for Pre-Bariatric Surgery Patients","Inclusion Criteria:\n\n* Be actively considering bariatric surgery.\n* Smoke at least 5 cigarettes daily for the past 3 months.\n* Have a BMI ≥ 30.0 kg\u002Fm2.\n* Not currently taking medications that interact with Naltrexone or Bupropion (e.g., opiates, benzodiazepines).\n* No history of medical conditions that are contraindicated with Naltrexone or Bupropion (e.g., seizure disorders, uncontrolled hypertension, cardiac issues including history of heart attacks, heart disease, or stroke, history of anorexia or bulimia nervosa).\n* Physically well enough to participate in the intervention (e.g., able to walk independently).\n* Speak\u002Fread\u002Fwrite in English.\n* Be 18-65 years old.\n* Not currently pregnant or breastfeeding or have plans to become pregnant or breastfeed during the study.\n* No active suicidal or homicidal ideation.\n\nExclusion Criteria:\n\n* Has a predisposition to seizures (e.g., subject with a history or evidence of seizure disorder, febrile seizures during childhood, brain tumor, cerebrovascular disease, or significant head trauma; has a family history of idiopathic seizure disorder or is currently being treated with medications or treatment regimens that lower seizure threshold).\n* Has a history of anorexia nervosa or history of bulimia nervosa.\n* Is currently taking a medication that is contraindicated to Naltrexone or Bupropion (e.g., MAOIs, opiates).\n* Has a history of allergy or sensitivity to Naltrexone or Bupropion.\n* Has a co-existing psychiatric condition that requires hospitalization or more intensive treatment (such as bipolar mood disorders, psychotic illnesses, or severe depression).\n* Has untreated hypertension with a seated systolic blood pressure \\> 160 mmHg, diastolic blood pressure \\> 100 mmHg, or heart rate \\> 100 beats\u002Fminute.\n* Has a history of congenital heart disease, cardiovascular disease, cardiac arrhythmias requiring medication, or a history of cerebrovascular pathology including stroke.\n* Has current uncontrolled Type I or Type 2 diabetes mellitus.\n* Has a history of severe renal, hepatic, neurological, chronic pulmonary, or gallbladder disease, or any other unstable medical disorder.\n* Is breast-feeding or is pregnant or is not using a reliable form of birth control.\n* Reports active suicidal or homicidal ideation.",{"count":155,"type":20},20,[87],"The purpose of this research study is to develop and pilot a multiple health behavior change intervention for weight loss and smoking cessation using medication (Naltrexone + Bupropion) and behavior therapy in adults seeking bariatric surgery.",[114,115,29],"2026-03-16",{"date":140,"type":39},{"date":162,"type":39},"2026-03-02",{"date":164,"type":20},"2027-12-31",{"name":100,"class":46},{"id":167,"slug":168,"hasResults":11,"nctId":169,"briefTitle":170,"officialTitle":171,"acronym":4,"eligibilityCriteria":172,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":56,"enrollmentInfo":173,"targetDuration":4,"studyType":21,"phases":175,"briefSummary":176,"conditions":177,"keywords":179,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":181,"lastUpdatePostDateStruct":182,"startDateStruct":184,"completionDateStruct":186,"leadSponsor":188,"locationsCount":47},"100597877","tap-block-timing-study-100597877","NCT07064200","TAP Block Timing Study","Transversus Abdominis Plane (TAP) Blocks in Bariatric and General Surgery: Does Timing Matter?","Inclusion Criteria:\n\n* Adults aged between 18 and 65 years\n* Scheduled for elective bariatric surgery or other elective general abdominal surgeries\n* Proficient in English sufficient to understand study procedures and communicate effectively\n* Capable of providing informed consent\n\nExclusion Criteria:\n\n* Individuals under 18 years of age (minors)\n* Pregnant individuals\n* Prisoners\n* Individuals with cognitive impairments or otherwise unable to provide informed consent independently\n* Individuals with known allergies or contraindications to local anesthetics used in TAP blocks",{"count":174,"type":20},150,[23],"This study investigates whether administering TAP blocks pre-incision provides superior postoperative pain control and reduces opioid use along with other medications compared to post-incision administration in patients undergoing elective abdominal surgeries.",[178,29],"Bariatric or General Abdominal Surgeries",[180],"bariatric analgesia","2026-01-26",{"date":183,"type":39},"2026-01-27",{"date":185,"type":39},"2025-07-14",{"date":187,"type":20},"2027-07",{"name":189,"class":46},"Weill Medical College of Cornell University",{"id":191,"slug":192,"hasResults":11,"nctId":193,"briefTitle":194,"officialTitle":195,"acronym":196,"eligibilityCriteria":197,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":198,"targetDuration":4,"studyType":21,"phases":200,"briefSummary":201,"conditions":202,"keywords":209,"overallStatus":116,"whyStopped":4,"lastUpdateSubmitDate":214,"lastUpdatePostDateStruct":215,"startDateStruct":217,"completionDateStruct":219,"leadSponsor":221,"locationsCount":47},"100608462","digital-preparation-for-bariatric-surgery-feasability-pilot-trial-100608462","NCT07201870","Digital Preparation for Bariatric Surgery: Feasability Pilot Trial","A Pilot Feasibility Study of the Implementation, Usability, Acceptability and Effectiveness of an Online Bariatric Surgery Preparation Platform","Pilot Be-Ready","Inclusion Criteria:\n\n* Be on the waiting list for metabolic and bariatric surgery at IUCPQ\n* not yet assessed by the local team and with an expected wait time of more than 6 months\n* understand French\n* Have an active email address\n\nExclusion Criteria:\n\n* Be part of the same household as someone already involved in this research project",{"count":199,"type":20},1050,[23],"Metabolic and bariatric surgery (MBS) is in increasing demand due to the growing prevalence of severe obesity and the cumulating evidence of long-term benefits on weight loss, cardiometabolic and functional health outcomes, and quality of life for individuals living with severe obesity. The time spent on the waiting list for an MBS follow the same trend with an estimated waiting time of more than 18 months and rising. The lack of resources and multidisciplinary capabilities among MBS centers impacts the quality of care and outcomes, which greatly contributes to delayed surgery. In 2023, 31% of patients who had an initial appointment with the MBS nurse at the Quebec Heart and Lung Institute - Laval University(IUCPQ) did not proceed with the surgery due to fear, uncertainty, or timing issues. Additionally, 49% reported that their concerns (e.g., financial, home support) were not addressed before MBS. These data highlight the urgent need to implement strategies to optimize wait time and ensure that MBS preparation is tailored to patients' expectations. Telehealth has significantly impacted surgical preparation, including for MBS, by enhancing accessibility, reducing dropout rates, and maintaining clinical outcomes that are comparable to traditional in-person visits but it requires real-time multidisciplinary execution, limiting the applicability for MBS waiting list patients. An interesting complement to telehealth intervention is online education platforms which offer digital flexibility, a significant advantage over in-person session.\n\nTo date, most MBS online resources are fee-based or driven by commercial interests and lack of clinical evidence, which raises concerns about their efficacy and safety for users who are seeking reliable support during their MBS journey.\n\nA free online education platform could optimize the time spent on the MBS waiting list by increasing patients' readiness for MBS, furnishing invaluable insights into the patient journey to MBS, and empowering individuals undergoing MBS. The IUCPQ is in the process of working on the care trajectory of patients with obesity. The Healthcare Direction and the Bariatric Surgery Clinic decided to use a platform called Precare. This platform offers personalized educational content as well as a calendar and appointment management system. It has been accredited by the Quebec Ministry of Health and Social Services. The present research focuses on the pilot testing the implementation and effectiveness of the PreCare solution for patients awaiting bariatric surgery at the IUCPQ.\n\nThe objectives of the research proposal are: 1) To assess the usability and acceptability of the Precare platform using a mixed design methodology; 2) To evaluate the logistical feasibility of using the platform in a clinical setting; 3) To determine whether extensive self-questionnaire assessments may impact the use of the Precare platform; 4) To explore barriers and facilitators to enhance patient engagement and knowledge retention; and 5) To derive estimates variables related to gender, ethnicity, cultural background, learners and psychological profiles for future phases.\n\nOur hypotheses are:\n\n1. The Precare platform will exhibit high usability and acceptability.\n2. Testing the Precare platform in real clinical settings is viable and will yield promising results for improving patient readiness for Metabolic and Bariatric Surgery.",[114,29,203,204,205,206,207,208],"Online Education","eHealth Literacy","Online-Intervention","Usability Satisfaction","Implementation Strategies","Shared Decision Making",[210,211,212,213],"obesity","bariatric surgery","preparation","education platform","2025-09-23",{"date":216,"type":39},"2025-10-01",{"date":218,"type":20},"2025-10-15",{"date":220,"type":20},"2028-10-01",{"name":222,"class":46},"Laval University",{"id":224,"slug":225,"hasResults":11,"nctId":226,"briefTitle":227,"officialTitle":228,"acronym":4,"eligibilityCriteria":229,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":230,"targetDuration":4,"studyType":21,"phases":231,"briefSummary":232,"conditions":233,"keywords":237,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":243,"lastUpdatePostDateStruct":244,"startDateStruct":246,"completionDateStruct":248,"leadSponsor":250,"locationsCount":47},"100566699","phase-2-oral-acetaminophen-for-post-op-pain-management-in-bariatric-surgery-patients-100566699","NCT06658574","Oral Acetaminophen for Post-Op Pain Management in Bariatric Surgery Patients","Comparative Efficacy of Two Different Oral Dosage Forms of Acetaminophen for Post-operative Analgesia in Bariatric Surgery Patients","Inclusion Criteria:\n\n* Adults aged 18 years old or greater who meet patient selection criteria for either primary Roux-en-Y gastric bypass or primary laparoscopic sleeve gastrectomy.\n\nExclusion Criteria:\n\n* Patients with a known hypersensitivity or history of intolerance to acetaminophen or any inactive ingredients in either formulation. Patients uncomfortable with or unable to take pills.\n* Surgical: Duodenal Switch (DS) surgeries, Adjustable Gastric Banding (AGB), surgical revisions, and surgical conversions.\n* Medical: patients with documented history of chronic and\u002For current pain syndrome, as evidenced by documentation of ICD-10 code G89.4, patients with documented ICD-10 code F11.90, indication unspecified, uncomplicated opioid use.\n* Patients of vulnerable populations, as outlined by federal guidelines as children, prisoners, pregnant women, and mentally disabled persons will be excluded.",{"count":174,"type":20},[111],"Adult patients with morbid obesity who have had Roux-en-Y gastric bypass (RYGB) or laparoscopic sleeve gastrectomy (LSG) surgery have impaired drug metabolism. There is a paucity of information available on how these patients metabolize acetaminophen post operatively and if drug preparation has any effect on achieving adequate pain control. The surgery may alter the stomach pH, reduce surface area of the stomach, affect transit time, and alter anatomic and physiologic standard absorption of medications. Due to these anatomic and physiologic changes, we seek to understand the potential effects of liquid versus pill formulations of acetaminophen on pain control in this patient population. The purpose of this study is to assess for subjective and objective measures of optimized pain control between formulations of acetaminophen including oral pills and oral liquid.",[234,28,235,29,236],"Post Operative Analgesia","Bariatric Surgery (Gastric Bypass)","Perioperative Analgesia",[238,239,240,241,242],"Acetaminophen","Bariatric","Analgesia","Perioperative","Post Operative","2025-04-01",{"date":245,"type":39},"2025-04-02",{"date":247,"type":39},"2024-11-13",{"date":249,"type":20},"2026-05",{"name":251,"class":46},"Rutgers, The State University of New Jersey",{"id":253,"slug":254,"hasResults":11,"nctId":255,"briefTitle":256,"officialTitle":257,"acronym":4,"eligibilityCriteria":258,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":259,"targetDuration":4,"studyType":59,"phases":4,"briefSummary":261,"conditions":262,"keywords":4,"overallStatus":116,"whyStopped":4,"lastUpdateSubmitDate":264,"lastUpdatePostDateStruct":265,"startDateStruct":267,"completionDateStruct":269,"leadSponsor":271,"locationsCount":47},"100585367","bariatric-surgery-for-obesity-100585367","NCT06901440","Bariatric Surgery for Obesity","Metabolic Biomarkers and Clinical Outcomes in Obesity: a Comparative Study of Surgical and Non-Surgical Cohorts","Inclusion Criteria:\n\n* Two groups:\n\n  * Intervention group: 25 adults (BMI ≥30) undergoing sleeve gastrectomy or Roux-en-Y gastric bypass.\n  * Control group: 25 adults (BMI ≥30) managed with lifestyle\u002F dietary interventions.\n\nExclusion Criteria:\n\n* Prior bariatric surgery, inflammatory bowel disease, antibiotic\u002Fprobiotic use (past 3 months), or severe hepatic\u002Frenal dysfunction.",{"count":260,"type":20},50,"Obesity has reached pandemic proportions worldwide, and its increased prevalence is associated with a plethora of metabolic disturbances. The obese state is characterized by increased adipose tissue mass and disturbed function resulting in systemic lipid spillover and low-grade inflammation, which may contribute to the development of comorbidities such as type 2 diabetes mellitus (T2DM) and cardiovascular disease. The crosstalk between various metabolic organs such as the gut, liver, adipose tissue, and skeletal muscle plays an important regulatory role in energy and substrate metabolism, which impacts metabolic health. The studies on the gut microbiota in host energy and substrate metabolism, \\& its relation to Obesity are neumerous, includes interventions that modify the gut microbiota composition and functionality with antibiotics , prebiotics \\& probiotics .\n\nObesity-associated with metabolic conditions such as ( Non alcoholic fatty liver diseases )NAFLD.\n\nObesity-associated NAFLD includes a spectrum of histological abnormalities ranging from steatosis to the inflammatory form of NAFLD, known as NASH. It is frequently seen in severe obesity, and its prevalence has been found to increase up to 90% in such patients in some countries.\n\nSo, in this study we compare liver status regarding degree of Steatosis among different patients, using Serum Biomarkers Scores and imaging techniques in obese patients undergo bariatric surgery ( case group ), and obese patients taking other lines of treatment ( Control group ); to detect if Bariatric surgery has better outcome for Steatosis and inflammatory markers than other lines of management for obesity.\n\n\\- Research outcome measures:\n\na. Primary (main):\n\n* Compare liver status regarding steatosis using Serum Biomarkers Scores in obese patients undergo bariatric surgery and obese patients taking other lines of treatment.\n* Correlate these changes with weight loss and glycemic control.\n* Secondary (subsidiary):\n* Evaluate associations between these scores and insulin resistance, lipid profiles and inflammatory markers.",[263,29],"Obesity and Obesity-related Medical Conditions","2025-03-23",{"date":266,"type":39},"2025-03-30",{"date":268,"type":20},"2025-04",{"date":270,"type":20},"2027-03",{"name":272,"class":46},"Assiut University",{"id":274,"slug":275,"hasResults":11,"nctId":276,"briefTitle":277,"officialTitle":277,"acronym":4,"eligibilityCriteria":278,"healthyVolunteers":55,"sex":16,"minAge":17,"maxAge":56,"enrollmentInfo":279,"targetDuration":4,"studyType":59,"phases":4,"briefSummary":281,"conditions":282,"keywords":287,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":295,"lastUpdatePostDateStruct":296,"startDateStruct":298,"completionDateStruct":300,"leadSponsor":302,"locationsCount":47},"100568382","the-role-of-nutrition-in-muscle-function-of-bariatric-surgery-patients-100568382","NCT06680492","The Role of Nutrition in Muscle Function of Bariatric Surgery Patients","Inclusion Criteria:\n\n* Male and female\n* Aged 18 to 65 years old\n* Undergoing first bariatric surgery (any type)\n* Diabetics and non-diabetics\n* Non-smokers and non-cannabis consumers\n\nExclusion Criteria:\n\n* Pregnant and breastfeeding women\n* Individuals undergoing second bariatric surgery\n* Regular smokers and cannabis consumers\n* Current use of Ozempic (or Ozempic-like medication) and anti-psychotic meds\n* Limited physical mobility (using walking aids such as canes, walkers, or wheelchairs) and issues with hand resistance\n* Kidney disease, non-controlled \u002F unstable hypertension and hypothyroidism, and any metabolic disease other than diabetes",{"count":280,"type":20},75,"Current recommendations for protein intake after bariatric surgery are not based on strong scientific evidence. It remains unclear how much protein should be eaten to minimize muscle loss and preserve the metabolism and function of individuals post-bariatric surgery.\n\nThe objective of this study is to analyze the relationships between changes in body composition, nutrition and protein intake, and muscle function after bariatric surgery to further our understanding of the nutritional needs of patients after bariatric surgery.\n\nWe intend to recruit around 75 participants, men and women, aged between 18 and 65 years. Participants will be recruited from the Bariatric Surgery Clinic, McGill University Health Center.",[283,284,285,286,29],"Obesity, Diabetes, Nutrition, Physical Health","Body Composition Changes","Muscle Function, Handgrip Strength Test","Protein Metabolism",[114,288,289,66,290,291,292,293,294],"Bariatric sugery","Protein function","6-Minute Walk Test","Handgrip Strength Test","Nutritional needs","Nutritional guides","Nutrition","2024-11-06",{"date":297,"type":39},"2024-11-08",{"date":299,"type":39},"2017-06-23",{"date":301,"type":20},"2026-01",{"name":303,"class":46},"Concordia University, Montreal"]